Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension

• Status: Unknown status
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the effectiveness of the synthetic analogue of prostacyclin in postembolic residual pulmonary hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Meshalkin Research Institute of Pathology of Circulation
• Treatments: Iloprost; Warfarin

Criteria

Inclusion Criteria:

• Patients with pulmonary embolism after undergone surgical treatment (intravascular thrombolysis, catheter thrombus fragmentation)

• Patients with preserved thromboembolism in the pulmonary circulation system and mean pressure in the pulmonary artery of more than 25 mm Hg

Exclusion Criteria:

• Patient did not sign the informed consent.

• Mean pulmonary artery pressure after surgical treatment less than 25 mm Hg

• Age above 75 years.

• Patients with an increased risk of bleeding - including gastric ulcer and 12 duodenal ulcer in acute, hemorrhagic stroke.

• Severe coronary artery disease (unstable angina, myocardial infarction within the last 6 months).

• Acute heart failure or CHF IV in NYHA.

• Severe arrhythmias.

• Pregnancy, lactation.

• The presence of severe diseases of other organ systems that may result in death during the first year after surgery.